Viewing data from:

LANTHANUM CARBONATE

ANDA

LANTHANUM CARBONATE | A206868 | INVAGEN PHARMACEUTICALS INC

3 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: FOSRENOL(TE code: AB)

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
Shire Development LLC et al v. InvaGen Pharmaceuticals, Inc. 2:2014cv07263 3 patentsANDA 206868lanthanum carbonate	NYED	2014-12-12	Terminated 2015-01-16	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

API Supply Chain12 active DMFs3 inactive

10 active API suppliers hold Drug Master Files for this ingredient.

MATRIX PHARMACORP PRIVATE LTDLANTHANUM CARBONATE

DMF 219582008

NATCO PHARMA LTDLANTHANUM CARBONATE DIHYDRATE

DMF 220502008

EXCELLA GMBH AND CO KGLANTHANUM CARBONATE

DMF 220942008

UNIMARK REMEDIES LTDLANTHANUM CARBONATE OCTAHYDRATE

DMF 232542009

SYMED LABS LTDLANTHANUM CARBONATE

DMF 282172014

MATRIX PHARMACORP PRIVATE LTDLANTHANUM CARBONATE (PROCESS 2)

DMF 334082018

ALKEM LABORATORIES LTDLANTHANUM CARBONATE OCTAHYDRATE

DMF 352982020

SOLARA ACTIVE PHARMA SCIENCES LTDLANTHANUM CARBONATE TETRAHYDRATE

DMF 370172022

SOLARA ACTIVE PHARMA SCIENCES LTDLANTHANUM CARBONATE OCTAHYDRATE

DMF 370182022

ZENJI PHARMACEUTICALS (SUZHOU) LTDLANTHANUM CARBONATE

DMF 370582023

ZHEJIANG GUOBANG PHARMACEUTICAL CO LTDLANTHANUM CARBONATE

DMF 393212023

ZENJI PHARMACEUTICALS (RIZHAO) LTDLANTHANUM CARBONATE

DMF 429572025

JOHNSON MATTHEY INCInactiveLANTHANUM CARBONATE

DMF 127221997

BOEHRINGER INGELHEIM CHEMICALS INCInactiveLANTHANUM CARBONATE HYDRATE

DMF 187862005

SIGNA SA DE CVInactiveLANTHANUM CARBONATE HYDRATE

DMF 280082014

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — EQ 500MG BASE

0 patents0 exclusivities▴

TABLET, CHEWABLE;ORAL | Approved: Jan 24, 2022

No patent or exclusivity listings for this strength.

#002 — EQ 750MG BASE

0 patents0 exclusivities▾

TABLET, CHEWABLE;ORAL | Approved: Jan 24, 2022

#003 — EQ 1GM BASE

0 patents0 exclusivities▾

TABLET, CHEWABLE;ORAL | Approved: Jan 24, 2022